VANCOUVER, British Columbia, & SEATTLE, Wash.– Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.
SōRSE Technology sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and over 12 months shelf stability. SōRSE Technology is science and data-driven, with 53 employees, 30 of whom specialize in R&D and Quality Assurance. SōRSE currently has multiple partnerships which provide a profitable revenue stream.
SōRSE technology will enable other cannabinoid researchers to build a network of doctors and scientists that can lead the world in offering cannabinoid health solutions. Pascal is the first company to identify a mechanism for cannabinoids to directly benefit cancer immunotherapy and is also developing a cannabinoid-derived drug targeting glioblastoma.
Pascal Biosciences is actively evaluating cannabinoid application research studies for potential participation. As a reputable cannabinoid industry leader, SōRSE Technology will partake in Pascal approved studies for the advancement of the industry and pharmaceutical applications.
“The potential of Pascal’s cannabinoid programs for clinical applications in combination with SōRSE’s proprietary emulsification methods offers a promising path for future medical applications of cannabinoid products,” said Dr. Patrick Gray, CEO of Pascal Biosciences. “This agreement comes on the heels of recent, successful collaborative efforts with SōRSE that allowed us to examine SōRSE formulations in several Pascal ongoing studies. The combination of SōRSE’s industry-leading technology with Pascal’s long-term biotech potential make this a meaningful transaction for our shareholders.”
“At SōRSE, we’re driven by our mission to help people better their lives through superior cannabinoid ingredients and delivery methods,” said SōRSE CEO Howard Lee. “We are excited to continue to support pharmaceutical studies of cannabinoids with the world-class researchers of Pascal Biosciences.”
About Pascal Biosciences Inc.
Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. Pascal will continue to work on this program, focusing on monoclonal antibodies for Acute Lymphoblastic Leukemia.
For more information, visit www.pascalbiosciences.com.
About SōRSE Technology
SōRSE Technology is a water-soluble emulsion technology designed for product developers to provide consumers with a better cannabis experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Their patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for seamless integration as an ingredient in food items, beverages, topicals, and medical applications.
SōRSE Technology currently powers more than 30 market-leading products in the cannabis, hemp and CBD industry. SōRSE‘s expertise allows for 360 degree solutions for product developers with minimal disruption to existing production procedures and methods. From sourcing ingredients to product formulation, the SōRSE team provides its partners unprecedented product safety and quality while optimizing compound bioavailability. Partnership opportunities include licensing, white labeling, product development, and cannabinoid research studies. SōRSE Technology is currently available in North America, South America, Europe, and Australia.
Julie Rathbun for Pascal Biosciences
Richard Laermer for SōRSE Technology
Tel: 212-741-5106 X 216
Interested inCannabinoid Research?SōRSE Biosciences
Looking to integrate CBD or Hemp into your portfolio? We’d love to learn more about your business and work to create a custom solution.
Tell us a little about your yourself and we’ll be in touch shortly